EC approves Zaltrap for mCRC

The European Commission approved Zaltrap aflibercept from Sanofi (Euronext:SAN; NYSE:SNY) in combination with FOLFIRI chemotherapy to treat metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin-containing regimen. Sanofi, which is co-developing Zaltrap with Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) under a 2003 deal, said it plans to launch the product later this year. The pharma said it will negotiate the price with local governments. Regeneron was down $0.74 to $169.94 on Tuesday. ...